Administration schedule of daunorubicin for elderly patients with acute myelogenous leukemia: A single-institute experience

Abstract

We evaluated the efcacy of daunorubicin (40 mg/m2/day for 5 days, 200 mg/m2/cycle) com-bined with standard dose of cytarabine (100 mg/m2/day for 7 days) for acute myelogenous leukemia patients aged 65-74 years as induction therapy. Complete remission (81.3%) was achieved in 13 of 16 patients following the therapeutic program. The median duration of reco-vering absolute neutolophilic counts over 1000/ml and platelet counts over 100 000/μl were 33 days and 27 days, respectively. None of the patients had any adverse cardiac compli-cations or died during administration of the induction therapy. Patients achieving complete remission received post-remission therapy consisting of two regimens other than induction therapy. The 3-year disease-free and overall survival rates were 36.9 and 50.0%, respect-ively. Extending the total period of the daunorubicin therapy might be an alternative to increasing the daily dose of daunorubicin in the induction therapy for elderly patients who were candidates for receiving intensied chemotherapy. © The Author (2011). Published by Oxford University Press. All rights reserved.